PHILADELPHIA, May 8, 2024 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship eCOA solution, TrialMax®. By leveraging process and technology enhancements, Signant’s operational teams can reduce the time it takes to go live with electronic patient-reported outcomes solutions by thirty percent or more.  

Sponsors and Contract Research Organizations (CROs) have relied on Signant’s eCOA solution for over 20 years. The solution is known for its flexibility, reliability, scientific support, global logistics support, and ability to scale to any size trial, anywhere in the world. Traditionally, the time to bring the system live for patients and sites was commensurate with the operational complexity and trial design.  
According to the company, customers can now benefit from this highly customizable eCOA solution along with Signant’s leading levels of science, scale, and service – delivered under much faster timelines.
“We are excited to offer customers the best of both worlds,” said Sanjiv Waghmare, Signant’s chief product officer. “They can get the fully featured, market-leading eCOA solution they already use and love, at a much faster pace. We believe this is especially meaningful as trial designs continue to increase in complexity. We want to ensure our customers hit their FPFV dates and start collecting high quality data without worrying about if their eCOA solution will be available.”    
According to Waghmare, Signant’s engineering and operational teams identified areas where process enhancements and automation could dramatically reduce common implementation steps regardless of trial complexity. These steps cover all aspects of a typical eCOA timeline including study build, testing, translations, scale management, and validation.
“This is just the beginning of our efforts to deliver complexity at speed, with outstanding quality,” continued Waghmare. “We are also bringing additional efficiencies to our processes that will accelerate post-implementation support, including reporting, analytics, and data change management.”
Signant also offers a tenured solution for eCOA studies as part of its Signant SmartSignals® Unified Platform, which is fully integrated with EDC, RTSM, eConsent, and telemedicine. For more information about all Signant’s eClinical solutions, go to www.signanthealth.com.
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Contact: 
Heather [email protected]+1 610.400.4141
Logo – https://mma.prnewswire.com/media/1202052/Signant_Health_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/signant-health-extends-ecoa-leadership-position-through-operational-innovations-that-reduce-timelines-by-at-least-one-third-302138773.html

NEW YORK, May 8, 2024 /PRNewswire/ — Ness Digital Engineering (Ness), a global full-lifecycle digital services transformation company, has acquired Intricity, a leading provider of data strategy, governance, modernization, and monetization solutions. The acquisition deepens Ness’s data offerings, which global F1000 clients have utilized to create new revenue streams and improve operating efficiencies.

“Ness has always had a strong capability in data engineering, and the acquisition of Intricity brings the data strategy and advisory capability. Furthermore, Ness will build on Intricity’s strategic alliances with Snowflake and Databricks,” said Ranjit Tinaikar, CEO, Ness Digital Engineering. “We are excited to welcome Intricity’s talented team to Ness, combining our strengths to deliver even greater value to our clients.”
Intricity brings deep expertise in handling complex data modernization and monetization problems that are the heart of any digital transformation today.
“Joining Ness, backed by KKR, presents an exciting opportunity to accelerate our growth trajectory worldwide. We are excited to leverage Ness’s global presence, digital competencies, and deep industry expertise to deliver digital transformation solutions to a wider range of clients,” said Arkady Kleyner, Principal & Co-Founder, Intricity. “Together, we are well-positioned to drive meaningful business outcomes and accelerate innovation for our clients.”
Commenting on the acquisition, Troy Clemente, Principal & Co-Founder, Intricity, added, “We have successfully established ourselves as experts covering the entire information lifecycle, and by joining Ness, we can accelerate our combined clients’ AI journeys based on modern data infrastructures.”
Zinnov acted as financial advisor to Ness Digital Engineering. 
For more information:Tanaya Misra, Global Head – PR & [email protected] 
About Ness Digital Engineering
Ness Digital Engineering, which funds managed by global investment firm KKR acquired in 2022, is a full-lifecycle digital engineering firm offering digital advisory through scaled engineering services. Headquartered in New York, Ness serves our customers across 11 innovation hubs in the US, Eastern Europe, and India. Combining our core competence in engineering with the latest in digital strategy and technology, we seamlessly manage Digital Transformation journeys from strategy through execution to help businesses thrive in the digital economy. For more information, visit www.ness.com. 
Logo: https://mma.prnewswire.com/media/2144213/4406841/Ness_Blue_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/ness-digital-engineering-acquires-intricity—a-new-york-based-company-specializing-in-data-strategy-governance-modernization-and-monetization-302139799.html

LONDON, May 8, 2024 /PRNewswire/ — The new Competitive Assessment by global technology intelligence firm ABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & gene manufacturing. The companies evaluated and ranked are:

Market Leaders: Körber Pharma, Siemens, Apprentice,  Rockwell Automation, and TulipMainstream: Dassault Systèmes, GE Digital, Honeywell, Emerson, MPDV, MasterControl, ParsecFollowers: Sepasoft
“Overall, the MES software market for pharmaceutical, biotechnology, and cell & gene manufacturing is highly competitive, and the top innovators offer very comparable solutions. Technology vendors are aggressively developing new functionality, and competitors must closely watch and identify areas where they can match or leapfrog software capabilities,” explains James Prestwood, Industrial & Manufacturing Industry Analyst at ABI Research.
A total of ten overarching criteria were chosen for the purposes of this analysis and segmented across innovation and implementation clusters. These include how comprehensive the solution is and what innovative functionality it offers, data visibility, accessibility, and security within the platform, the user experience, and the capacity of worker augmentation, the MES’s contribution to manufacturers digital thread capabilities, and the alignment of the MES software with the pharmaceutical, biotechnology, and cell & gene manufacturing markets. In addition, the report evaluates MES vendor’s ability to deliver rapid time to value, their experience in delivering the software to manufacturers, the extensiveness of the vendor’s partnership base, the support for SME manufacturers, and the comprehensiveness of the software’s pricing options.
Körber Pharma and Siemens came out on top in the competitor ranking, with both firms scoring well across all criteria. Apprentice ranked as the top innovator in the assessment, offering a wide range of strong functionality designed specifically for life sciences manufacturing, an excellent cloud-native design, and comprehensive low/no-code capabilities.  Dassault Systèmes scored particularly well in the implementation criteria, ranking second, with its center-of-excellence deployment model allowing manufacturers to quickly and consistently deploy and scale DELMIA Apriso.
“Pharmaceutical, biotech, and cell & gene manufacturing have been slow to embrace digital transformation but are now catching up. The industry’s strict regulations mean new solutions must be proven, and a premium should be placed on extensive deployment experiences when choosing solutions and technology partners,” Prestwood concludes.
These findings are from ABI Research’s MES Software for Pharmaceutical, Biotech, and Cell & Gene Therapy Manufacturing Competitive Ranking report. This report is part of the company’s Industrial and Manufacturing Markets research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Competitive Ranking reports offer comprehensive analysis of implementation and innovation strategies to offer unparalleled insight into a company’s performance and standing compared to its competitors.
About ABI Research
ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.
ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info:
GlobalDeborah Petrara Tel: +1.516.624.2558 [email protected] 
Logo – https://mma.prnewswire.com/media/2309035/4693374/ABI_Research_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/korber-pharma-and-siemens-take-the-lead-in-abi-researchs-mes-software-for-pharmaceutical-biotechnology-and-cell–gene-manufacturing-competitive-ranking-302139303.html